Allogeneic hematopoietic stem cell transplantation (HSCT), [3] [4] [5] [6] [7] [8] [9] particularly following a reduced-intensity conditioning (RIC) regimen, [7, [10] [11] [12] is a promising strategy for treatment of advanced-stage MF/SS.
In this study, we retrospectively analyzed the outcomes of RIC-HSCT for advanced-stage MF/SS and found that MF/SS appears to be susceptible to graft-versus-lymphoma (GVL) effects.
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Materials and methods
Patients
We studied outcomes in a consecutive series of 9 patients with MF/SS who underwent Staging of the disease was performed according to the criteria of the ISCL / EORTC. [13] Large cell transformation was defined as the presence of more than 25% of large cells in biopsied samples. [14] [15] [16] 
Transplantation procedures
All of the patients were treated with a RIC regimen. Graft-versus-host disease (GVHD) prophylaxis consisted of the combination of a calcineurin inhibitor (CI) and short-term 7 methotrexate (sMTX). Granulocyte colony-stimulating factor was administered from day 5 until neutrophil engraftment. The prophylactic regimen for infection included levofloxacin, an antifungal agent (fluconazole, itraconazole or micafungin), and acyclovir.
Definitions
Treatment response was evaluated according to the Consensus WHO criteria for MF/SS. 
Statistical analysis
Probabilities of OS, progression-free survival (PFS) and after HSCT were estimated using 8 Kaplan-Meier estimates. Statistical analyses were performed with EZR, which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0). [19] 
Results
Patients' characteristics
The median age of the patients was 42 years, ranging from 22 to 57 years. Seven patients had MF and two had SS. Eight of those 9 patients had large cell transformation. All patients had advanced disease (stage IIB: n=2, IIIB: n=1, IVA2: n=5, and IVB: n=1). The median interval from disease onset to HSCT was 12 years, ranging from 3 to 23 years. All of the patients received at least 4 lines of treatments prior to HSCT. Disease status at transplant was CR in only one patient and PR in 8 patients. All PR patients had cutaneous disease and four of them had involvement of other lesions including the lymph nodes and peripheral blood ( Table 1) .
Transplant characteristics
Types of HSCT were bone marrow transplantation in 6 patients, peripheral blood stem cell transplantation in 3 patients, and cord blood transplantation in one patient (Table 2) 
Engraftment and GVHD
All patients tolerated the conditioning regimen and achieved neutrophil engraftment (median: 14 days, range: 12 to 22 days). Acute GVHD developed in 8 patients (grade 2: n=7, grade 4: n=1). All of the patients had stage 2 to 4 cutaneous GVHD. Chronic GVHD developed in 7 patients (mild: n=1, moderate: n=2, severe: n=4).
Relapse and GVL effects
Eight patients who underwent transplantation at PR attained CR after HSCT. However, relapse occurred early after HSCT in 5 patients (55.6%) at a median of 45 days and range of 32 to 84 days after HSCT. All of the relapse patients had taken CI at the time of relapse and CI was rapidly tapered off, followed by donor lymphocyte infusion (DLI) in 2 patients. With these immunomodulations, GVHD developed and CR was achieved again in 4 (80%) of the 
Discussion
Our study suggests that RIC-HSCT is a promising strategy for the treatment of advanced MF/SS; 3-year OS was 85.7% without NRM. Duarte et al. reported that the 3-year OS rate in 60 patients with advanced MF/SS who underwent allogeneic HSCT was 54% and that an RIC regimen improved transplant outcome due to less NRM than that in the case of a 14 myeloablative conditioning (MAC) regimen (3-year OS: 63% vs 29%, 2-year NRM: 49% vs 14%). [7] In another retrospective large-scale study by de Masson A et al., 2-year OS was 56% and 3-year PFS was 31%, and the type of conditioning regimen (RIC versus MAC) had no significant impact on transplant-related mortality. [9] The excellent outcome in our study is likely due to less NRM than that in other studies.
HSCT for MF/SS is often complicated with severe bacterial infection due to disruption of the skin barrier by the skin lesions of MF/SS. [20] [21] [22] In our study, such severe infection events were not observed. All of our patients received RIC regimens, in which the severity of cytopenia is mild and the risk of severe infection is reduced compared to those in MAC regimens.
In addition, disease could be managed relatively easily after relapse following HSCT by the immunomodulations. Early relapse of MF was observed in 5 patients; however, in 4 patients whose relapse was detected only from the skin, persistent CR was achieved in 1 patient and the disease was manageable in other 3 patients by the treatment of immunomodulations, including the tapering of immunosuppressants and DLI, suggesting that GVL effect and "down-staging effect" from advanced-stage to early-stage by HSCT improve the prognosis of advanced-stage MF/SS. Such a GVL effect against MF/SS mediated by the tapering of immunosuppressants and DLI has been reported previously. Alloreactive donor T cells that have infiltrated into the skin to cause GVHD may also attack MF/SS cells mostly present in the skin, leading to a potent GVL effect. However, development of severe GVHD severely affects quality of life and survival of patients. Actually in our study, high incidence of both acute and chronic GVHD was observed, and most of them developed after the tapering of immunosuppressants or DLI. Fortunately, there was no NRM, nevertheless control of both MF/SS and GVHD is often difficult.
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Relapse rate was high after HSCT in our study. This may be due to the use of an RIC regimen and a higher proportion of non-CR patients than those in other studies. It should be noted that all disease relapses occurred within 100 days after HSCT in our study. These results urge us to develop novel strategies to prevent relapse after RIC-HSCT without 
